Aridis Pharmaceuticals (ARDS) Gets a Buy Rating from H.C. Wainwright

In this article:

In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Aridis Pharmaceuticals (ARDSResearch Report), with a price target of $19.00. The company’s shares closed last Thursday at $2.80.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.1% and a 36.1% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Eledon Pharmaceuticals, Citius Pharmaceuticals, and Achieve Life Sciences.

Aridis Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $16.67.

See the top stocks recommended by analysts >>

Based on Aridis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $515K and GAAP net loss of $21 million. In comparison, last year the company had a GAAP net loss of $5.79 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-105, AR-101, AR-401, AR-201, and AR-501. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in San Jose, CA.

Read More on ARDS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

Latest News Feed